1-8 of 8
Dick Pluim
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract CT154: Phase I dose-escalating PoC study to evaluate the safety and tolerability of LiPlaCis (liposomal cisplatin formulation) in patients with advanced or refractory tumors

Ulrik Lassen, Morten Mau-Sørensen, Ulla Hald Buhl, Mogens W. Madsen, Eva Balslev, Dick Pluim, Jan H. M. Schellens, Steen Knudsen, Peter B. Jensen
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): CT154.
https://doi.org/10.1158/1538-7445.AM2016-CT154
Published: 15 July 2016
View article titled, Abstract CT154: Phase I dose-escalating PoC study to evaluate the safety and tolerability of LiPlaCis (liposomal cisplatin formulation) in patients with advanced or refractory tumors
Journal Articles

Abstract 966: Effect of ABC drug transporters (BCRP, MDR1, MRP2) on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA .

Serena Marchetti, Dick Pluim, Monique van Eijndhoven, Olaf van Tellingen, Roberto Mazzanti, Jos Beijnen, Jan HM Schellens
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 966.
https://doi.org/10.1158/1538-7445.AM2013-966
Published: 15 April 2013
View article titled, Abstract 966: Effect of ABC drug transporters (BCRP, MDR1, MRP2) on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA .
Journal Articles

Gemcitabine metabolite, 2’,2’-difluorodeoxyuridine (dFdU), can be phosphorylated and incorporated into nucleic acids

Stephan Veltkamp, Maria van Eijndhoven, Dick Pluim, Maria Bolijn, Robert Jansen, Ignacio Garcia-Ribas, Enaksha Wickremsinhe, Jos Beijnen, Jan Schellens
Journal: Cancer Research
Cancer Res (2007) 67 (9_Supplement): 1541.
Published: 01 May 2007
View article titled, Gemcitabine metabolite, 2’,2’-difluorodeoxyuridine (dFdU), can be phosphorylated and incorporated into nucleic acids
Journal Articles

The novel orally available taxane derivative BMS-275,183 is a substrate for P-glycoprotein (Pgp, MDR1) and MRP2 and interacts with benzimidazole proton pump inhibitors.

Serena Marchetti, Dick Pluim, Olaf Van Tellingen, Thomas W. Griffin, Michael H. Woo, Jos H. Beijnen, Roberto Mazzanti, Jan H. Schellens
Journal: Cancer Research
Cancer Res (2006) 66 (8_Supplement): 1272.
Published: 15 April 2006
View article titled, The novel orally available taxane derivative BMS-275,183 is a substrate for P-glycoprotein (Pgp, MDR1) and MRP2 and interacts with benzimidazole proton pump inhibitors.
Journal Articles

ABC- transporter studies of Gimatecan (7-t-butoxyiminomethylcamptothecin) in comparison to topotecan

Serena Marchetti, Roos Oostendorp, Dick Pluim, Olaf Van Tellingen, Alfred H. Schinkel, Richard Versace, Jos H. Beijnen, Roberto Mazzanti, Jan H. Schellens
Journal: Cancer Research
Cancer Res (2006) 66 (8_Supplement): 145.
Published: 15 April 2006
View article titled, ABC- transporter studies of Gimatecan (7-t-butoxyiminomethylcamptothecin) in comparison to topotecan
Journal Articles

The Effect of Bcrp1 (Abcg2) on the In vivo Pharmacokinetics and Brain Penetration of Imatinib Mesylate (Gleevec): Implications for the Use of Breast Cancer Resistance Protein and P-Glycoprotein Inhibitors to Enable the Brain Penetration of Imatinib in Patients

Pauline Breedveld, Dick Pluim, Greta Cipriani, Peter Wielinga, Olaf van Tellingen, Alfred H. Schinkel, Jan H.M. Schellens
Journal: Cancer Research
Cancer Res (2005) 65 (7): 2577–2582.
https://doi.org/10.1158/0008-5472.CAN-04-2416
Published: 01 April 2005
View article titled, The Effect of Bcrp1 (Abcg2) on the <em>In vivo</em> Pharmacokinetics and Brain Penetration of Imatinib Mesylate (Gleevec): Implications for the Use of Breast Cancer Resistance Protein and P-Glycoprotein Inhibitors to Enable the Brain Penetration of Imatinib in Patients
Open the PDF for The Effect of Bcrp1 (Abcg2) on the <em>In vivo</em> Pharmacokinetics and Brain Penetration of Imatinib Mesylate (Gleevec): Implications for the Use of Breast Cancer Resistance Protein and P-Glycoprotein Inhibitors to Enable the Brain Penetration of Imatinib in Patients in another window
Journal Articles

Mechanism of the Pharmacokinetic Interaction between Methotrexate and Benzimidazoles: Potential Role for Breast Cancer Resistance Protein in Clinical Drug-Drug Interactions

Pauline Breedveld, Noam Zelcer, Dick Pluim, Özgür Sönmezer, Matthijs M. Tibben, Jos H. Beijnen, Alfred H. Schinkel, Olaf van Tellingen, Piet Borst, Jan H. M. Schellens
Journal: Cancer Research
Cancer Res (2004) 64 (16): 5804–5811.
https://doi.org/10.1158/0008-5472.CAN-03-4062
Published: 16 August 2004
View article titled, Mechanism of the Pharmacokinetic Interaction between Methotrexate and Benzimidazoles: <subtitle>Potential Role for Breast Cancer Resistance Protein in Clinical Drug-Drug Interactions</subtitle>
Open the PDF for Mechanism of the Pharmacokinetic Interaction between Methotrexate and Benzimidazoles: <subtitle>Potential Role for Breast Cancer Resistance Protein in Clinical Drug-Drug Interactions</subtitle> in another window
Journal Articles

Overexpression of the BCRP/MXR/ABCP Gene in a Topotecan-selected Ovarian Tumor Cell Line

Marc Maliepaard, Margôt A. van Gastelen, Laurina A. de Jong, Dick Pluim, Robert C. A. M. van Waardenburg, Marjan C. Ruevekamp-Helmers, Ben G. J. Floot, Jan H. M. Schellens
Journal: Cancer Research
Cancer Res (1999) 59 (18): 4559–4563.
Published: 15 September 1999
View article titled, Overexpression of the <em>BCRP/MXR/ABCP</em> Gene in a Topotecan-selected Ovarian Tumor Cell Line
Open the PDF for Overexpression of the <em>BCRP/MXR/ABCP</em> Gene in a Topotecan-selected Ovarian Tumor Cell Line in another window